Skip to main content
Book cover

Pharmacotherapy of Pulmonary Hypertension

  • Book
  • © 2013

Overview

  • Written by leading experts in the field of pulmonary hypertension
  • Broadens your understanding of current, evidence-based pharmacological treatments of various forms of pulmonary hypertension
  • Comprehensive review of most recent developments in this field including new signaling pathways
  • Includes supplementary material: sn.pub/extras

Part of the book series: Handbook of Experimental Pharmacology (HEP, volume 218)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Softcover Book USD 379.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (22 chapters)

  1. Pulmonary Hypertension: Conceptual Bases of the Disease

  2. Pulmonary Hypertension: Established Therapies

  3. Pulmonary Hypertension: Novel Pathways and Emerging Therapies

Keywords

About this book

This volume focuses on current evidence-based pharmacological treatments of various forms of pulmonary hypertension and provides a comprehensive review of the latest developments in this area. The first part of the book covers the definition, classification, pathophysiology, pathology, biomarkers and animal models of the disease, thus laying the conceptual basis for what follows. The middle section provides an overview of the established therapies, such as calcium channel blockers, prostanoids, endothelin receptor antagonists, phosphodiesterase-5 inhibitors and inhaled nitric oxide. The last section explores novel pathways and emerging therapeutic approaches including soluble guanylate cyclase stimulators, Rho-kinase inhibitors, inhibitors of serotonin receptors and transporters, peptide growth factors, vasoactive peptides, modulators of redox equilibrium and cyclic nucleotide homeostasis, as well as immunosuppressive and anti-proliferative agents. Particular attention is given to the clinical applications of these experimental therapies, that are on the horizon. The book thus spans the continuum from basic science to clinical applications.

Editors and Affiliations

  • Faculte´ de Me´decine, Univ Paris-Sud, Le Kremlin Bicêtre, France

    Marc Humbert

  • Dep of Anasthesia and Critical Care, Harvard Medical School Massachusetts General Hospital, Boston, USA

    Oleg V. Evgenov

  • Cardiovascular Research, Bayer Pharma AG, Wuppertal, Germany

    Johannes-Peter Stasch

Bibliographic Information

Publish with us